RxDoctor Payments Data

Chantelle Allen, NP

Family · Terre Haute, INNPI 1942737010

Payments from drug & device makers

$4,055in general payments, 2019–2025

Across 193 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$312
  • Collegium Pharmaceutical, Inc.$310
  • MML US, Inc.$277
  • Amgen$272
  • Teva Pharmaceuticals USA, Inc.$263
  • AstraZeneca$232
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$3,94397%
  • Education$1113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,055 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$4,802
Medicare patients
47
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl85$65,951
RelistorMethylnaltrexone Bromide14$34,862
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,186$27,160
Xtampza ErOxycodone Myristate37$26,919
BrixadiBuprenorphine13$18,903
Buprenorphine46$13,512
Aimovig AutoinjectorErenumab-Aooe12$8,883
HorizantGabapentin Enacarbil11$8,671
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl69$8,225
Pregabalin194$8,091
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen270$7,258
Morphine Sulfate ErMorphine Sulfate145$4,523
OxycontinOxycodone Hcl13$3,401
Gabapentin219$2,916
Lidocaine22$2,458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$310$92,870122 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$17$34,86214 claims
Braeburn Inc.Brixadi$200$18,90313 claims
Arbor Pharmaceuticals, Inc.Horizant$65$8,67111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.

Other family in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →